news.cision.com

PExA AB (“PExA”) has been named the awardee in the “Carcinogenic Exposure Meter QuickFire Challenge”, sponsored by Johnson & Johnson Innovation - JLABS, the Lung Cancer Initiative (LCI) at Johnson & Johnson, and Janssen Research & Development, LLC.As the awardee of the QuickFire Challenge, PExA will receive $250,000 in grant funding, mentorship and coaching from experts at Johnson & Johnson Innovation, the LCI and Janssen Research & Development, LLC, and access to the Johnson & Johnson Innovation - JLABS global entrepreneurial community.The Challenge invited innovators from across the

NATTO: INVITATION TO PRESENTATION OF SECOND HALF AND PRELIMINARY FULL YEAR 2018 FINANCIAL RESULTS

Oslo, Norway (06 February 2019) — NattoPharma will release its second half and preliminary full year 2018 financial results on Wednesday 13th February 2019 at approximately 08:00 CET. The report will be made available at www.nattopharma.com and at www.oslobors.no. The same day, starting at 10:00 am, the company will host a webcast with a presentation of the results, followed by an online Q&A session. Please follow the below link to join the web-cast, http://webtv.hegnar.no/presentation.php?webcastId=97603094 For more information, please contact: Kjetil Ramsøy CEO,

The Nomination Committee’s proposal for Board of Directors of Indutrade AB for the 2019 Annual General Meeting

The Nomination Committee proposes re-election of Katarina Martinson as Chairwoman of the Board at the 2019 Annual General Meeting. The Committee also proposes the re-election of Board members Susanna Campbell, Bengt Kjell, Anders Jernhall, Ulf Lundahl, Krister Mellvé, Lars Pettersson and Bo Annvik. The Nomination Committee’s proposal entails that the number of Board members (eight) will remain unchanged during the forthcoming term of office. Indutrade’s Annual General Meeting will be held on 9 May 2019. Stockholm, 6 February 2019 The Nomination Committee For further

Notice of extraordinary shareholders meeting in Camanio Care AB

Shareholders in Camanio Care AB (publ), corporate registration number 556761–0307, will hold an extraordinary shareholders meeting on Wednesday February 20, 2019, at 10.00 a.m. at the company’s offices at address Hästholmsvägen 32, 131 30 Nacka, Sweden.Registration and right to participation Shareholders who wish to participate in the shareholders meeting shall · be registered as a shareholder in the shareholders registry maintained by Euroclear Sweden AB no later than Wednesday February 13, 2019. · inform the company of their intent to participate in the shareholders meeting no

Increased investments – mass market developing faster than expected

October–December 2018 · Net sales totalled SEK 14,961 thousand (10,506), which corresponds to an increase of 42 per cent. · Operating profit/loss totalled SEK -15,628 thousand (-14,814). Earnings are developing according to plan as a result of investments, mainly in personnel, to meet the continued increasing level of activity in the Automotive Solutions business area. · Profit/loss after financial items was SEK -15,681 thousand (-14,984). · Profit/loss after tax per share was negative. · Cash and cash equivalents totalled SEK 89,946 thousand at 31 December. · The company

Year-End Report, 1 January – 31 December 2018

FOURTH QUARTER SUMMARY, OCTOBER–DECEMBER 2018 · Net sales increased to SEK 840 m (778), up 8 per cent. · EBITA increased to SEK 105 m (102), for an EBITA margin of 12.5 per cent (13.1). · Operating profit increased to SEK 80 m (77), for an operating margin of 9.5 per cent (9.9). · Profit after tax increased to SEK 67 m (55). · Earnings per share increased to SEK 2.00 (1.81). · Cash flow from operating activities increased to SEK 114 m (65). SUMMARY OF SIGNIFICANT EVENTS DURING THE FOURTH QUARTER, OCTOBER–DECEMBER 2018 · Swedish Energy Agency and Swedish

Alelion Energy Systems appoints Carnegie as financial advisor

The Board and Management of Alelion Energy Systems AB (publ) has appointed Carnegie Investment Bank AB (publ) as financial advisor. Carnegie will assist Alelion Energy Systems in evaluating the company’s capital structure and possible future financing alternatives.For further information, please contact: Daniel Troedsson President and CEO Alelion Energy Systems AB 0707-51 67 10 About Alelion Energy Systems AB (publ) Alelion Energy Systems AB is a leading

Alfa Laval wins SEK 75 million energy efficiency order

Alfa Laval – a world leader in heat transfer, centrifugal separation and fluid handling – has won an order to supply compact heat exchangers to a refinery and petrochemical plant in China. The order has a value of approximately SEK 75 million. It is booked in the Welded Heat Exchangers unit of the Energy Division, with deliveries scheduled for 2019 and 2020.The order comprises Alfa Laval compact heat exchangers which will be used to recover and reuse heat in the refinery, which produces both transportation fuels and feedstock for petrochemical production. “I am pleased to announce this

Invitation to the Annual General Meeting

Neste Corporation Stock Exchange Release 6.2.2019 at 9.30 am. (EET) Neste Corporation's shareholders are hereby invited to the Annual General Meeting of Shareholders (AGM) to be held on Tuesday, 2 April 2019, beginning at 1.00 pm EET, in the Helsinki Fair Centre at Messuaukio 1, 00520 Helsinki. Registration and the distribution of voting papers will begin at 12.00 noon EET.A. Matters to be handled and the agendaThe following matters will be discussed and decided at the AGM:1. Opening of the meeting2. Calling the meeting to order3. Election of the examiners of the minutes and

PowerCell receives order for fuel cell systems from Tier 1 automotive supplier

PowerCell Sweden AB (publ) has received an order for two MS-30 fuel cell systems from a global automotive tier 1 supplier for delivery in Q1/Q2 2019.The English version is an in house-translation. In case of any discrepancy, the Swedish text will prevail. The systems are built around PowerCell’s fuel cell stack S2 and with an effect of 30 kW. The supplier will install the systems as range extenders, REX, in vehicles for tests in China. The customer is a global tier 1 supplier to the automotive industry. PowerCell MS-30 fuel cell system has been developed with the specific purpose to

Realisation of Kesko's share-based commitment and incentive plan for the 2017-2018 performance period

Kesko Corporation’s Board of Directors has decided, based on the fulfilment of the performance criteria of the share-based commitment and incentive plan (PSP), to grant a total of 142,850 of its own B shares held by the Company as treasury shares to the members of management and other selected key persons who were included in the target group for the 2017-2018 performance period. This number of shares represents gross earnings, from which the applicable withholding tax is deducted and the remaining net amount is paid to the participants in shares. Kesko’s share-based commitment and

Reminder: C-RAD Web Presentation Year-end Report 2018

Wed, Feb 06, 2019 08:20 CET

Presentation of the report for the fiscal year 2018: Date: Friday February 8, 2019 / kl. 13:00 CET Venue: Online Presentation Topic: C-RAD Year-end Report 2018 Procedure: Please register online through the website: https://attendee.gotowebinar.com/register/9056807416721220353 After your registration, you will receive a confirmation via email. A recording of the presentation will be made accessible on the C-RAD website after the presentation. About C-RADC-RAD develops innovative solutions for use in advanced radiation therapy. The C-RAD group offers products

Shareholders' proposals to the Annual General Meeting for the composition of Kesko's Board of Directors and the Board’s remuneration

Kesko Corporation's shareholders jointly holding over 10% of the votes attached to the Company’s shares have made a proposal to the Annual General Meeting to be held on 8 April 2019 regarding the number of Board members, their remuneration and the reimbursement of their expenses. Proposal for the number of Board members Kesko Corporation's shareholders jointly holding over 10% of the votes attached to the Company’s shares have proposed that the Company’s Annual General Meeting resolves that the number of Board members is seven (7). Proposal for the remuneration of Board members and

Kesko Board's proposals to the Annual General Meeting

Wed, Feb 06, 2019 08:10 CET

Kesko Corporation's Board of Directors has decided to propose to the Annual General Meeting convened for 8 April 2019 that the dividend payable for the year 2018 be €2.34 per share, that sections 6, 9 and 10 of the Company’s Articles of Association be amended, and that the Board be authorised to decide on donations for charitable purposes. The Board proposes that Authorised Public Accountants PricewaterhouseCoopers Oy be elected as the Company’s auditor. Kesko Corporation's shareholders are invited to the Annual General Meeting to be held at Messukeskus Helsinki, Rautatieläisenkatu 3,

Gunnebo Year-end Release 2018

Wed, Feb 06, 2019 08:01 CET

Strong Cash Flow and Continued Sales Growth in Q4CEO Comments on performance for the Quarter – Continuing Operations"During the fourth quarter, the Group’s sales growth was 6%, coming from growth in all four Business Units of Safe Storage, Cash Management, Entrance Control and Integrated Security. Safe Storage grew by 8% mainly driven by strong sales of SafeStore Auto and continued strong sales of ATM safes. Cash Management grew by 12% due to very strong sales of closed cash management, SafePay, and CIT solutions. Entrance Control continued to grow and increased by 3% in the fourth

US FDA grants Fasenra Orphan Drug Designation

6 February 2019 07:00 GMT US FDA grants Fasenra Orphan Drug Designation for hypereosinophilic syndrome The US Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to Fasenra (benralizumab) for the treatment of hypereosinophilic syndrome (HES). HES is a group of rare, potentially fatal disorders characterised by high numbers of eosinophils in blood and tissues, which can cause progressive damage to any organ in the body.1,2 The FDA grants ODD status to medicines intended for the treatment, diagnosis or prevention of rare diseases or disorders that affect

The nomination committee’s proposal regarding the Board for the 2019 Annual General Meeting

The Nomination Committee proposes that the Board shall be composed of eight directors elected at the AGM, with no alternates, for the period until the next AGM. The Nomination Committee proposes re-election of Marianne Brismar, Kenth Eriksson, Martin Lundstedt, Anders Nielsen, Susanna Schneeberger, Martin Sköld, Claes Magnus Åkesson as directors and election of Karin Gunnarsson as new director. It is proposed that Kenth Eriksson be re-elected Chairman of the Board. Karin Gunnarsson was born in 1962. She holds a Degree of Master of Science in Business and Economics from the Stockholm

Year-end report January-December 2018

October-December 2018• Net sales for the fourth quarter amounted to SEK 3,390 million (3,116).• Organic growth was a negative 2 per cent (0).• Operating profit amounted to SEK 109 million (282). Operating profit was impacted by a pension cost of SEK 66 million, which is recognised as an item affecting comparability, and by non-recurring costs of SEK 88 million.• Operating profit excluding items affecting comparability and including non-recurring costs amounted to SEK 175 million (282), corresponding to an operating margin, excluding items affecting comparability, of 5.2 per cent (9.

Year-end report 2018